Intrathecal Delivery of ssAAV9-DAO Extends Survival in SOD1^sup G93A^ ALS Mice

• Published in: Neurochemical research 2017-04, Vol.42 (4), p.986
• Main Authors: Wang, Wan, Duan, Weisong, Wang, Ying, Wen, Di, Liu, Yakun, Li, Zhongyao, Hu, Haojie, Cui, Hongying, Cui, Can, Lin, Huiqian, Li, Chunyan
• Format: Article
• Language: English
• ISSN: 0364-3190; 1573-6903
• DOI: 10.1007/s11064-016-2131-6

Amyotrophic lateral sclerosis (ALS) is an adult-onset, irreversible neurodegenerative disease that leads to progressive paralysis and inevitable death 3-5 years after diagnosis. The mechanisms underlying this process remain unknown, but new evidence indicates that accumulating levels of d-serine result from the downregulation of d-amino acid oxidase (DAO) and that this is a novel mechanism that leads to motoneuronal death in ALS via N-methyl-d-aspartate receptor-mediated cell toxicity. Here, we explored a new therapeutic approach to ALS by overexpressing DAO in the lumbar region of the mouse spinal cord using a single stranded adeno-associated virus serotype 9 (ssAAV9) vector. A single intrathecal injection of ssAAV9-DAO was made in SOD1G93A mice, a well-established mouse model of ALS. Treatment resulted in moderate expression of exogenous DAO in motorneurons in the lumbar spinal cord, reduced immunoreactivity of d-serine, alleviated motoneuronal loss and glial activation, and extended survival. The potential mechanisms underlying these effects were associated with the down-regulation of NF-[kappa]B and the restoration of the phosphorylation of Akt. In conclusion, administering ssAAV9-DAO may be an effective complementary approach to gene therapy to extend lifespans in symptomatic ALS.